Sign Up for Free!

Continue Analyzing the page and more.

Continue with Google

Already have an Account? Log In

The Trial has ended

Continue Analyzing the page and more.

Upgrade to Pro
Home Daily Intelligence Tracker
    • Plans Blog Contact
    iSpecimen Inc logo
    ISPC

    iSpecimen Inc

    MaveScore 25 Low model confidence
    Last Price US$2.43 As of Jul 10, 2026
    Market Cap US$2.0b Company size context
    7D Performance -7.95% Past 7 days
    1Y Performance 122.94% Past 12 months
    Model Rating
    Historical model output for research review

    Fundamental data date

    Mar 31, 2026

    102 days old

    Market price date

    Jul 10, 2026

    1 day old

    Coverage

    16/16

    No missing model inputs

    Data quality

    Excellent

    Current stored snapshot

    Transparent research score

    Why the model scores this stock

    MaveScore is a research prioritization score from 0 to 100. It is historical model output for watchlist review, not personalized financial advice.

    MaveScore 25 Low confidence

    Stored data quality

    Freshness and coverage checks

    16/16 Current stored snapshot

    Quality

    7/35 Weak

    Blends latest model rank with profitability and dilution ranks.

    Financial Strength

    3/25 Weak

    Rewards durable profitability, margins, and positive free cash flow.

    Valuation Support

    0/15 Weak

    Favors positive earnings, positive cash flow, and lower multiples.

    Momentum

    15/15 Strong

    Highlights research candidates with supportive 3-month and 6-month price regimes.

    Shareholder Alignment

    0/10 Weak

    Rewards less dilutive share behavior and enough size for liquid research coverage.

    Positive model output

    • Highlights research candidates with supportive 3-month and 6-month price regimes.

    Research risks to review

    • Blends latest model rank with profitability and dilution ranks.
    • Rewards durable profitability, margins, and positive free cash flow.
    • Favors positive earnings, positive cash flow, and lower multiples.

    MaveScore uses historical model inputs, stored company fundamentals, and stored price context for research support only. Review missing inputs and business-specific risks before acting.

    Overview Earnings Report Price History News Competitors Earnings per Share Return on Equity Net Margin Share Buyback Leverage Financial Statements Financial Ratio
    Dashboard Funda..tals Prediction Screener Map

    iSpecimen Inc Overview

    Industry: Diagnostics & Research

    Sector: Healthcare

    iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, labs, biobanks, blood centers, and other healthcare organizations. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. The company was incorporated in 2009 and is headquartered in Lexington, Massachusetts. iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patie Read More

    iSpecimen Inc is evaluated based on the investment philosophy and approach to stock market investing developed by renowned investor Warren Buffett. Companies with high ratings typically exhibit growing earnings, a substantial profit margin, conservative leverage, a consistently high return on equity, and a sustained practice of repurchasing their shares over the years.

    iSpecimen Inc

    Score

    Reported Results

    What the company reported, with filing details kept small.

    Filed Aug 06, 2024

    Quarterly result summary

    Revenue was $258.9M (-38% YoY). Net loss was -$2.1M.

    Revenue $258.9M -38% YoY
    Net loss -$2.1M reported

    What changed

    • Revenue -38% YoY to $258.9M.

    Guidance / outlook

    No formal outlook was extracted from this filing excerpt. Open the SEC source to review full management commentary.

    Earnings release Open filing

    Source: SEC EDGAR company-filed earnings materials. Dates are shown only for verification; review the source filing before relying on extracted report details.

    Other recent earnings materials
    SEC filing QUARTERLY REPORT May 18, 2026 SEC filing ANNUAL REPORT Apr 01, 2026 SEC filing QUARTERLY REPORT Nov 17, 2025 SEC filing QUARTERLY REPORT Aug 14, 2025 SEC filing QUARTERLY REPORT May 19, 2025 SEC filing ANNUAL REPORT Apr 14, 2025 SEC filing 10-Q Nov 07, 2024 Earnings material EXHIBIT 99.2 Aug 06, 2024 SEC filing FORM 8-K Aug 06, 2024

    Recent News



    Should you wait for a breakout in ISPC - CPI Data & Stock Portfolio Risk Management
    2 days ago
    Certain Warrants of iSpecimen Inc. are subject to a Lock-Up Agreement Ending on 22-SEP-2025.
    2 days ago
    Update Recap: Will ISPC stock benefit from M&A - July 2025 News Drivers & AI Powered Trade Plan Recommendations
    4 days ago

    Earnings Per Share

    Score 3.00/5
    iSpecimen Inc boasts a high score, as its Earnings Per Share (EPS) has demonstrated consistent growth over the past six years. Notable counterparts in the sector with high scores includes Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    In Diagnostics & Research industry , IQVIA Holdings Inc , Agilent Technologies Inc , Thermo Fisher Scientific Inc are companies with high ratings.

    Return on Equity

    Score 0.80/5
    iSpecimen Inc exhibits a lower score in the Return on Equity (ROE) section, falling below the sector median value and indicating a comparatively weaker performance in this metric. The top companies in the same sector include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    iSpecimen In... ISPC US$2.0b
    Zoetis Inc ZTS US$31.4b
    IQVIA Holdin... IQV US$34.6b
    Agilent Tech... A US$36.9b

    Net Margin

    Score 0.55/5
    iSpecimen Inc olds a low score as its net margin consistently trails below the sector median value and doesn't exhibit continuous growth over the last six years; notable companies in the sector with commendable scores include Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc
    iSpecimen In... ISPC US$2.0b
    Zoetis Inc ZTS US$31.4b
    IQVIA Holdin... IQV US$34.6b
    Agilent Tech... A US$36.9b

    Share Buyback

    In Diagnostics & Research industry , IQVIA Holdings Inc , Agilent Technologies Inc , Thermo Fisher Scientific Inc are companies with high ratings.

    Leverage

    Score 2.79/5
    iSpecimen Inc attains a commendable score in the category due to its lower leverage ratio over the past six years in comparison to the sector median value. Additionally, other notable companies in the same sector, such as Zoetis Inc IQVIA Holdings Inc Agilent Technologies Inc , also exhibit high scores.
    iSpecimen In... ISPC US$2.0b
    Zoetis Inc ZTS US$31.4b
    IQVIA Holdin... IQV US$34.6b
    Agilent Tech... A US$36.9b

    Financial Statements

    Company-reported SEC EDGAR facts organized into the three core statements.

    SEC financial statements are temporarily unavailable.

    Source: SEC EDGAR companyfacts. Values are standardized company filings for research support, not personalized financial advice.

    Financial Ratio

    Yearly Quarterly

    Financial
    Profitability
    Growth
    Cash Flow
    Financial Health
    Efficiency Ratios

    iSpecimen Inc logo

    iSpecimen Inc

    US$2.43

    US$2.0b

    -7.95%

    122.94%